Post-mastectomy radiotherapy: recommended standards
|
|
- Melanie Bell
- 6 years ago
- Views:
Transcription
1 Post-mastectomy radiotherapy: recommended standards H. Bartelink Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands Introduction The local recurrence rate after mastectomy in breast cancer patients varies significantly in reported series; in some publications from 2% to even more than 50% at 10 years. The reasons for these differences can be found in patient selection and the surgical method and technical skills of the surgeon. For example, a low recurrence percentage can be obtained by combining a good surgical procedure with the exclusion of patients for radical mastectomy by following strict inoperability criteria. For this purpose, the following criteria are often used: fixation of the tumour and/or lymph nodes to the chest wall, inflammatory breast cancer, and in some institutes a positive axillary apex biopsy. In 1949 Ralston Paterson and colleagues in Manchester started probably the first randomized clinical trial in the world investigating the potential of radiotherapy in improving local control and indirectly survival [1]. They randomized patients after mastectomy between no radiotherapy and post-mastectomy radiotherapy. For this purpose 1461 patients were entered in this trial. He and his colleagues demonstrated that radiotherapy was able to reduce significantly the amount of local recurrences thereby preventing patients dying from symptoms of uncontrolled local disease. Unfortunately long term follow up showed that the potential gain in survival was diminished by an excess of radiotherapy-related cardiovascular complications. It would be unfair to criticize the trial design according to current standards and the radiation technique used but a few remarks should be made here. For example, the randomization was based on the patient's date of birth (odd or even), so the surgeon would know beforehand in which arm the patient would be randomized. He may have therefore decided not to select patients for the trial if they had a high risk of local recurrence knowing that they would be randomized to no further treatment. Instead he may have referred these patients for radiotherapy, leading to unbalanced treatment arms. The major reason for the excess of cardiovascular deaths seen in this trial was the equipment available at that time. The patients were treated with orthovoltage equipment using a technique that delivered a high dose to a large part of the heart with higher fraction doses. A reduction of the local recurrence rate, by a factor of 0.6, by post-mastectomy radiotherapy has now been confirmed by many trials. It took until recently for it to be demonstrated that improvement in local control could result in about 10% improved survival rate [2-4]. These results became available with the publication of the long term follow up data from a few major trials started after These trials have shown a gain that can be reached by careful selection of high-risk patients for radiotherapy and through the execution of meticulous radiotherapy techniques, avoiding over dosage of radiation to the heart. The impact of improved local control on the survival rate shown by these trials suggests that distant metastases may arise from recurrent local disease, stressing the need for adequate local treatment. The purpose of this lecture is to discuss the indications for post-mastectomy radiotherapy, the technique used and the avoidance of complications and also the interaction with adjuvant chemotherapy. Indications for post-mastectomy radiotherapy In an overview study of the literature, Recht [5] showed that the local recurrence rate in T3 or N4+ patients varied between 14 and 46%, despite receiving adjuvant chemotherapy, thus underlining the need for postoperative radiotherapy in these cases. Considering indications for postoperative radiotherapy one should always bear in mind the balance between the gain in local control and survival and the disadvantages of radiotherapy (see below). There is a general consensus that a locoregional recurrence rate of 20% at 10 years or more justifies postoperative radiotherapy. This percentage (or even higher) is frequently seen for patients with a microscopically incomplete resection, a T3 NO tumour with unfavourable histological signs or positive nodes and for patients with 4
2 8 H. Bartelink Table 1 Indications for postoperative chest wall irradiation Incomplete resection (micro- or macroscopic) 4 or more positive lymph nodes T3 tumours with grade 2 or 3 and/or vascular invasion T3 N+ tumours Diffusely growing tumours in more than one quadrant Table 2 Indications for postoperative irradiation of the axilla 4 or more positive nodes in 2 levels or 50% of the nodes are positive More than one palpable lymph node metastases of more than 2cm Margin of surgery less than 5 mm Extra nodal spread at the border of surgical specimen or more positive lymph node metastases (N4+). The indications for postoperative irradiation of the chest wall and axilla should be considered separately since the recurrence rate in the axilla is much lower than on the chest wall (Tables 1 and 2). Nowadays, the most difficult question concerns whether patients with Tl-2 and Nl still need postmastectomy radiotherapy, considering that in the Danish trials the major benefit in survival is seen in this patient group. The indications for post-mastectomy radiotherapy should therefore be discussed in a multidisciplinary team including the pathologist, the surgeon and the radiation oncologist. They should consider the surgical technique such as the adequacy of the axillary dissection and pathological factors associated with a high local recurrence rate such as vascular invasion and extra nodal spread together with the proximity of the tumour to the resection margins. The treatment of the internal mammary lymph nodes is still a matter for debate. The finding of involvement of these lymph nodes of 20-25% in, for example, the Milan experience and the impact of inadequate locoregional treatment on survival suggests that elective irradiation of these nodes may be of benefit to patients with an increased risk of internal mammary lymph node metastases. For this purpose a major EORTC trial is presently underway to investigate the benefit of irradiation of these lymph nodes. Acute side effects seen after radiotherapy are mainly skin reactions varying from redness to moist desquamation at the end of treatment Six weeks to 6 months after treatment, radiation pneumonia's can occur especially if a (too) large lung volume is irradiated. An increased incidence of radiation pneumonitis has been reported in patients receiving both radiotherapy and tamoxifen, although this has to be confirmed in a larger patient population [6]. Late side effects such as fibrosis and arm edema are seen mostly 2 years or more after the end of treatment. For evaluation of cardiovascular side effects a follow-up of 10 to 15 years is needed. Nowadays, the use of modern radiotherapy equipment allows the radiation oncologist to reduce significantly the dose to the heart and lungs. Tangential photon irradiation combined with direct irradiation fields to treat the internal mammary lymph nodes (technique A) (Fig. 1) may be replaced by a different technique with electrons or a combination of tangential beam irradiation with angled fields to treatment the internal mammary lymph nodes (technique B) (Fig. 2). If a simple tangential field technique is used the amount of cardiac complications can be estimated Fig. 1. Transverse slice through the middle of the breast showing the external contour, heart and lungs (technique A): note low dose region between the internal mammary fields and the tangential fields. Field outlines and 95% and 50% isodose lines are shown m. Reduction of side effects from radiotherapy -is Fig. 2. Transverse slice through the middle of the breast showing the external contour, heart and lungs (technique B). Field outlines and 95% and 50% isodose lines are shown [7].
3 Post-mastectomy radiotherapy: recommended standards by measuring the heart volume on the simulator film in case of left-sided breast cancer. In cases exceeding a limited volume (heart volume distance more than 1 cm) a different technique should be selected. A more modem way is to use intensity modulated radiotherapy (IMRT). With this approach the beams are angled and shaped according to the patient's contour, carefully avoiding critical normal tissues while being able to deliver curative doses to the chest wall, axilla and internal mammary lymph nodes [7]. Care should also be taken when using concomitant radiotherapy and chemotherapy, especially when anthracyclins, taxoids and/or trastuzumab are given. Due to limited follow-up, it is not known at this moment whether the combination of anthracyclins will later result in an increased rate of cardiovascular problems as seen in patients with small cell lung cancer. Another disadvantage of postoperative radiotherapy in breast cancer is the risk of arm edema, which can increase from 2-5% after mastectomy and axillary dissection alone to 20-30% when radiotherapy is added. Reduction of the risk of arm edema can be obtained by not exceeding the daily radiation dose of 2.5 Gy. Instructions to patients on how to prevent arm infections and their immediate treatment with antibiotics if this occurs, will help to reduce the incidence of arm edema. In case of edema, physiotherapy will help to reduce the swelling of the arm. Limiting the extent of the radiation fields to only the chest wall and lower part of the axilla will be possible in patients with a T3-4 tumour with only involvement of the nodes located in the lower part of the axilla. This adaptation will probably not lead to an increased incidence of arm edema after irradiation of the axilla and supraclavicular nodes. cancer has led to improved locoregional local control compared to radiotherapy alone [9,10]. As referred to earlier, adjuvant chemotherapy on its own is not able to reduce significantly the locoregional recurrence rate in high risk breast cancer patients. A combination of both treatment modalities is therefore often required. There is frequent debate whether chemotherapy should be given first or radiotherapy. In the past, the argument has often been used that postoperative radiotherapy has had no impact on survival and could therefore be delayed. This must now be considered differently as the extent of improvement in survival appears to be similar to that of adjuvant chemotherapy in these patients. Furthermore, up to now none of the meta-analyses have demonstrated a benefit of chemotherapy before or after standard local treatment. So the correct answer will remain uncertain for a while until major trial results in this area become available. One is inclined therefore not to postpone radiotherapy until after chemotherapy but to give it concomitantly as a 'sandwich' scheme: between two courses of chemotherapy [11-13]. In general it has been shown that this combination is well tolerated and few adaptations have to be made. As mentioned earlier, there is some concern in administering radiotherapy and chemotherapy concomitantly especially if anthracyclins are used. This combination may lead to an increase in cardiovascular problems as seen in patients with small cell lung cancer when doxorubicin was used concomitantly with radiotherapy. However reliable data are lacking in de literature and the concomitant combination may prove to be not that harmful if drugs such as anthracyclins, taxoids and trastuzumab are excluded. Timing of interval radiotherapy and surgery No major trials have been published investigating the optimal time interval between radiotherapy and surgery in breast cancer apart from a few small studies with conflicting results. Most retrospective studies in breast conserving therapy suggest that the interval between surgery and radiotherapy should preferably not exceed 6 weeks [8] as, with longer interval, more recurrences have been observed. Combination and timing of chemotherapy with post-mastectomy radiotherapy In many trials it has been shown that the combination of radiotherapy and systemic treatment in breast Improvement in locoregional control and survival by postoperative radiotherapy Over the many years that clinical randomized clinical trials have been performed, investigating the potential of postoperative radiotherapy, it has appeared that this approach has led to a consistent significant reduction of local recurrences. This approach resulted in a reduction by a factor 0.6 by adding radiotherapy after any form of mastectomy. This occurred both in the old trials using orthovoltage equipment, and in the recent clinical trials where modem megavoltage equipment has been used. Generally a locoregional recurrence rate of about 30% has been reduced to about 7-10% (Table 3). This gain in local control on its own is already a major benefit to patients by preventing symptoms from untreatable local progres-
4 10 H. Bartelink Table 3 Locoregional recurrences in patients who all received chemotherapy ± radiotherapy [2] ^^~ No radotfwrapy Treatment RT + CMF CMF alone Locoregional recurrence 75 (9%) 277 (32%) sion. It is important to realize also that only local cure can be obtained in about half of the patients with a local recurrence after mastectomy. Such a recurrence is an unfavourable sign as it is also frequently followed by the appearance of distant metastases. The trials executed before 1975 have not shown a benefit in survival; in contrast even a negative effect has been observed in some trials, mainly due to an excess of cardiovascular deaths [14]. In a recent update by the EBCTCG these findings were confirmed, showing both moderate benefits during the first decade or two, and moderate hazards that grow progressively larger with longer follow-up. The benefits demonstrate the important principle that improved control of local disease in early breast cancer implies, other things being equal, a moderate but definite reduction in the long-term risk of death from breast cancer [15]. If particular radiotherapy regimens (those that very strictly limit carotid and intrathoracic exposure) can be shown to yield most of the benefit while avoiding most of the hazard, 20 year survival could be improved in a wider range of patients [16]. The recent Danish and Vancouver trials have demonstrated that with modem radiotherapy the improved local control has been translated into a survival advantage of approximately 10% (Fig. 3). One may criticize some of these trials for having used rather low doses of chemotherapy. This diminishes the opportunity to further improve survival in these patients, although these trials may reflect the doses given in the large community. The negative impact Years after Mastectomy Fig. 3. Kaplan Meier Estimates of overall survival among women treated with radiotherapy plus CMF and CMF alone [2] Years Fig. 4. Cumulative mortality for ischemic heart disease by radiotherapy group [17]. of cardiovascular death caused by improper radiation techniques has not been seen up to now [17,18] (Fig. 4). Recommended reading... Seminars in Radiation Oncology, Volume 9 (3), 1999: special issue on adjuvant therapy of breast cancer (LJ Pierce and M Overgaard, eds.) References 1 Paterson R, Russell M. Breast cancer evaluation of postoperative radiotherapy. J Fac Radiol 1959; 10: Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Group DCG 82b randomised trial. N Engl J Med 1997; 337: Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal patients given adjuvant tamoxifen: Danish Breast Cancer Group DBCG 82c randomised trial. Lancet 1999; 353(9165): Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node positive premenopausal women with breast cancer. N Engl J Med 1997; 337: Recht A. Locoregional failure rates in patients with involved axillary nodes after mastectomy and systemic therapy. Semin Radiat Oncol 1999; 9: Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996; 88(13): Hurkmans CW, Bos L, Van der Horst A, et al: Estimation of cardiac and lung complications after breast cancer irradiation. Radiother Oncol 2000; in press. 8 Slotman BJ, Jeyer OW, Njo KH, et al. Importance of riming of radiotherapy in breast conserving treatment of early stage breast cancer. Radiother Oncol 1994; 30: Bartelink H, Rubens RD, Van der Schueren E, et al Hormonal therapy prolongs survival in irradiated locally advanced breast cancer, a European Organization for Research and Treatment of Cancer randomized phase DI trial. J din Oncol 1997; 15: Elkhuizen PH, Van Slooten HJ, Clahsen PC, et al. High local recurrence risk after breast-conserving therapy in node-nega-
5 Post-mastectomy radiotherapy: recommended standards 11 tive premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer, Breast Cancer Cooperative Group Study. J Clin Oncol 2000; 18: Maririewicz DA, Schultz DJ, Haas JA, et al. The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys 1996; 35: Borger J, Bartelink H. Does the sequence of radiotherapy and chemotherapy in breast-conserving therapy influence outcome? Cancer J Sci Am 1996; 2: Thames HD, Buchholz TA, Smith CD. Frequency of first metastatic events in breast cancer implications for sequencing of systemic and local-regional treatment J Clin Oncol 1999; 17: Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality on long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1995; 12: Early Breast Cancer Trialists' Collaborative Group: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer an overview of the randomised trials. Lancet 2000; 355(9217): Recht A, Bartelink H, Fourquet A, et al. Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol 1998; 16: H0jris I, Overgaard M, Christensen JJ, et al. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet 1999; 354: Kurtz JM. Radiotherapy for early breast cancer was a comprehensive overview of trials needed? Lancet 2000; 355(9217):
6
Oncologist. The. Controversies Regarding the Use of Radiation After Mastectomy in Breast Cancer
The Oncologist Controversies Regarding the Use of Radiation After Mastectomy in Breast Cancer THOMAS A. BUCHHOLZ, ERIC A. STROM, GEORGE H. PERKINS, MARSHA D. MCNEESE Department of Radiation Oncology, The
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationPostmastectomy radiotherapy and locoregional recurrence rate in high-risk breast cancer patients
Original article UDC: 618.19-006:618.19-089.87:615.849.1 Arch Oncol 2004;12(1):39-43. Postmastectomy radiotherapy and locoregional recurrence rate in high-risk breast cancer patients Danijela ÆEPANOVIÆ
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationMETASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER
Trakia Journal of Sciences, No 4, pp 7-76, 205 Copyright 205 Trakia University Available online at: http://www.uni-sz.bg ISSN 33-7050 (print) doi:0.5547/tjs.205.04.02 ISSN 33-355 (online) Original Contribution
More informationAcute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols
ORIGINAL ARTICLES Acute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols Mohamed Abdelhamed Aboziada 1, Samir Shehata 2 1 Department of Radiation Oncology, South Egypt
More informationRadiotherapy and Oncology
Radiotherapy and Oncology 9 (29) 74 79 Contents lists available at ScienceDirect Radiotherapy and Oncology journal homepage: www.thegreenjournal.com Postmastectomy irradiation High local recurrence risk
More informationRadiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015
Radiation Treatment for Breast Cancer Melissa James Radiation Oncologist August 2015 OUTLINE External Beam Radiation treatment. (What is Radiation, doctor?) Role of radiation. (Why am I getting radiation,
More informationCase Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
More informationNo clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study
Annals of Oncology original articles Annals of Oncology 26: 1149 1154, 2015 doi:10.1093/annonc/mdv159 Published online 3 April 2015 No clear effect of postoperative radiotherapy on survival of breast cancer
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationReal-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive lymph nodes: a retrospective study
Journal of Radiation Research, 2014, 55, 121 128 doi: 10.1093/jrr/rrt084 Advance Access Publication 20 June 2013 Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationCHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD ( ) - A RETROSPECTIVE ANALYSIS
Archive of Oncology 2000;8(Suppl 1):7. SESSION 1 CHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD (1995-2000) - A RETROSPECTIVE ANALYSIS 7 Archive of Oncology 2000;8(Suppl 1):8. 8 Extended
More information03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.
radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. Division of Radiation Oncology Allegheny Health Network Cancer Institute Professor of Radiation Oncology
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationRadiotherapy Physics and Equipment
Radiological Sciences Department Radiotherapy Physics and Equipment RAD 481 Lecture s Title: Introduction Dr. Mohammed EMAM Ph.D., Paris-Sud 11 University Vision :IMC aspires to be a leader in applied
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationGuidelines for the treatment of Breast cancer with radiotherapy v.1.0 September 2017
Guidelines for the treatment of Breast cancer with radiotherapy v.1.0 September 2017 Author: Dr Virginia Wolstenholme, Consultant Clinical Oncologist, Barts Health Date agreed: September 2017 Date to be
More informationGUIDELINES FOR RADIOTHERAPY IN EARLY BREAST CANCER
GUIDELINES FOR RADIOTHERAPY IN EARLY BREAST CANCER Authors: Dr N Thorp/ Dr P Robson On behalf of the Breast CNG Written: Originally - December 2008 Reviewed: Updated - December 2011 Agreed: Breast TSG
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 99, by the Massachusetts Medical Society VOLUME O CTOBER 2, 99 NUMBER POSTOPERATIVE RADIOTHERAPY IN HIGH-RISK PREMENOPAUSAL WOMEN WITH BREAST CANCER WHO RECEIVE
More informationEffects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes
Cancer Biol Med 2014;11:123-129. doi: 10.7497/j.issn.2095-3941.2014.02.007 ORIGINAL ARTICLE Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationConservative Surgery and Radiation Stage I and II Breast Cancer
Conservative Surgery and Radiation Stage I and II Breast Cancer Variant 1: Premenopausal 41-year-old woman, 1.1-cm GII IDC, upper outer quadrant (UOQ), ER/PR ( ), HER2 ( ), primary excised with lumpectomy,
More informationCombined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.
Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement. Ung O, Langlands A, Barraclough B, Boyages J. J Clin Oncology 13(2) : 435-443, Feb 1995 STUDY DESIGN
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationLocoregional Outcomes in Clinical Stage IIB Breast Cancer After Neoadjuvant Therapy and Mastectomy With or Without Radiation
Locoregional Outcomes in Clinical Stage IIB Breast Cancer After Neoadjuvant Therapy and Mastectomy With or Without Radiation Dayssy A. Diaz, MD, Judith Hurley, MD, Isildinha Reis, PhD, Cristiane Takita,
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationTreatment results and predictors of local recurrences after breast conserving therapy in early breast carcinoma
Journal of BUON 8: 241-246, 2003 2003 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Treatment results and predictors of local recurrences after breast conserving therapy in early breast
More informationThe Role of a Boost Radiation Dose in Patients with Negative Re-Excision Findings
24 The Open Breast Cancer Journal, 2011, 3, 24-28 Open Access The Role of a Boost Radiation Dose in with Negative Re-Excision Melanie C. Smitt and Kathleen C. Horst * Department of Radiation Oncology,
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje Jacoba
University of Groningen Local treatment in young breast cancer patients Joppe, Enje Jacoba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationBenefit of Internal Mammary Lymph Nodes Irradiation in Patients with Breast Cancer
Benefit of Internal Mammary Lymph Nodes Irradiation in Patients with Breast Cancer Amr El-Kashif, MD, Mohamed Abdelrahman, MD, Salah El-Mesidy, MD Department of Clinical Oncology, Faculty of Medicine,
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationPhilip Poortmans, MD, PhD
Past President President Elect Philip Poortmans, MD, PhD 2 To treat or not IMN: Balancing Risks and Benefits 3 Conflict of interest: I am a radiation oncologist 4 To treat or not to treat the IMN 1. Introduction
More informationRADIOTHERAPY FOR STAGE II AND STAGE III BREAST CANCER PATIENTS WITH NEGATIVE LYMPH NODES AFTER PREOPERATIVE CHEMOTHERAPY AND MASTECTOMY
doi:10.1016/j.ijrobp.2010.12.054 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. e1 e7, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front matter
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationThe Incidence of Lung Carcinoma after Surgery for Breast Carcinoma with and without Postoperative Radiotherapy
1362 The Incidence of Lung Carcinoma after Surgery for Breast Carcinoma with and without Postoperative Radiotherapy Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) Clinical Trials
More informationWhole Breast Irradiation: Class vs. Hypofractionation
Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer
More informationConcurrent Cyclophosphamide, Methotrexate, and 5-Fluorouracil Chemotherapy and Radiotherapy for Breast Carcinoma
696 Concurrent Cyclophosphamide, Methotrexate, and 5-Fluorouracil Chemotherapy and Radiotherapy for Breast Carcinoma A Well Tolerated Adjuvant Regimen Neil Isaac, B.Sc. 1 Tony Panzarella, M.Sc. 2 Anthea
More informationBreast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective. Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL
Breast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL Radiotherapy in Early Breast Cancer Why do we do it? Who
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationInvasive Breast Cancer
Invasive Breast Cancer Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationDepartment of Surgery, School of Medicine, Kyungpook National University, Daegu; 3
Original Article Radiat Oncol J 08;6(4):85-94 https://doi.org/0.857/roj.08.00458 pissn 4-900 eissn 4-56 Local and regional recurrence following mastectomy in breast cancer patients with positive nodes:
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationOral cavity cancer Post-operative treatment
Oral cavity cancer Post-operative treatment Dr. Christos CHRISTOPOULOS Radiation Oncologist Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Important issues RT -techniques Patient selection
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationPatient information. A scientific investigation of two different schedules of radiotherapy to patients operated for breast cancer
Patient information A scientific investigation of two different schedules of radiotherapy to patients operated for breast cancer Protocol title: Moderately hypofractionated loco-regional adjuvant radiation
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje Jacoba
University of Groningen Local treatment in young breast cancer patients Joppe, Enje Jacoba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationCONSERVATIVE therapy in the management of
Vol. 332 No. 14 BREAST CONSERVATION VERSUS MASTECTOMY IN STAGE I AND II BREAST CANCER 7 TEN-YEAR RESULTS OF A COMPARISON OF CONSERVATION WITH MASTECTOMY IN THE TREATMENT OF STAGE I AND II BREAST CANCER
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationThe New England Journal of Medicine ADJUVANT RADIOTHERAPY AND CHEMOTHERAPY IN NODE-POSITIVE PREMENOPAUSAL WOMEN WITH BREAST CANCER
ADJUVANT RADIOTHERAPY AND IN NODE-POSITIVE PREMENOPAUSAL WOMEN WITH BREAST CANCER JOSEPH RAGAZ, STEWART M. JACKSON, NHU LE, IAN H. PLENDERLEITH, JOHN J. SPINELLI, VIVIAN E. BASCO, KENNETH S. WILSON, MARGARET
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationEarly and locally advanced breast cancer: diagnosis and management
National Institute for Health and Care Excellence Final Early and locally advanced breast cancer: diagnosis and management [I] Evidence reviews for postmastectomy radiotherapy NICE guideline NG101 Evidence
More informationBruno CUTULI Policlinico Courlancy REIMS. WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ
Bruno CUTULI Policlinico Courlancy REIMS WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ XXI CONGRESSO AIRO GENOVA 22.11.2011 INTRODUCTION Due to wide diffusion of mammography,
More informationTreatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy
Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy Kyoung Ju Kim 1, Seung Jae Huh 1, Jung-Hyun Yang 2, Won Park 1, Seok Jin Nam
More informationOriginal Study. Abstract. Introduction. Clinical Breast Cancer February
Outcomes of Clinically Node-Negative Breast Cancer Without Axillary Dissection: Can Preserved Axilla Be Safely Treated With Radiation After a Positive Sentinel Node Biopsy? Naoko Sanuki, 1 Atsuya Takeda,
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationPavel ŠLAMPA, Jana RUZICKOVA, Barbora ONDROVA, Hana TICHA, Hana DOLEZELOVA
Sole conformal perioperative interstitial brachytherapy of early stage breast carcinoma using high-dose rate afterloading: longer-term results and toxicity Received: 0.09.2007 Accepted: 7.02.2008 Subject:
More informationPrediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography
Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography Eyad Fawzi AlSaeed 1 and Mutahir A. Tunio 2* 1 Consultant Radiation Oncology, Chairman
More informationM D..,., M. M P.. P H., H, F. F A.. A C..S..
Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationHypo- versus normofractionated radiation therapy of early breast cancer in the randomized DBCG HYPO trial
Hypo- versus normofractionated radiation therapy of early breast cancer in the randomized DBCG HYPO trial BV Offersen 1, HM Nielsen 1, EH Jacobsen 2, MH Nielsen 3, M Krause 4, L Stenbygaard 5, I Mjaaland
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationJ. Emami MD*, S. Hemati MD*, K. Mohammadian MD**
Original Article Evaluation of ECG changes after Radiotherapy of left chest wall by Electron in patients with left breast cancer who receive Anthracycline based chemotherapy following mastectomy J. Emami
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationSIGN. Management of breast cancer in women. December Scottish Intercollegiate Guidelines Network. A national clinical guideline
SIGN Scottish Intercollegiate Guidelines Network 84 Management of breast cancer in women A national clinical guideline 1 Introduction 1 2 Diagnosis, referral and investigation 2 3 Surgery 7 4 Radiotherapy
More informationAdvances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015
Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy
More informationMultidisciplinary management of breast cancer
Multidisciplinary management of breast cancer C. Polgár 1,2 1 National Institute of Oncology 2 Semmelweis University Department of Oncology Incidence of breast cancer in Hungary 2014 Female population
More informationStandard primary surgical treatment options for women
Review Synthèse Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy Pauline T. Truong, Ivo A. Olivotto, Timothy J. Whelan, Mark Levine,
More informationHow to sequence systemic therapies and radiotherapy in early breast cancer?
How to sequence systemic therapies and radiotherapy in early breast cancer? H. Wildiers, MD, PhD 1,2, T. Pecceu, MD 1, C. Weltens, MD, PhD 2,3, P. Neven, MD, PhD 2, S. Peeters, MD, PhD 2,3 Breast cancer
More informationHypofractionated radiotherapy for breast cancer: too fast or too much?
Editorial Hypofractionated radiotherapy for breast cancer: too fast or too much? Vassilis E. Kouloulias 1, Anna G. Zygogianni 2 1 2nd Department of Radiology, Radiotherapy unit, Attikon University Hospital,
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 2012 September; 15(3): 329-336 Radiation Treatment in Pathologic N0-N1 Patients Treated with Neoadjuvant Chemotherapy Followed by Surgery for Locally
More informationARROCase - April 2017
ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationAdvances in Localized Breast Cancer
Advances in Localized Breast Cancer Melissa Camp, MD, MPH and Fariba Asrari, MD June 18, 2018 Moderated by Elissa Bantug 1 Advances in Surgery for Breast Cancer Melissa Camp, MD June 18, 2018 2 Historical
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationIORT What We ve Learned So Far
IORT What We ve Learned So Far The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationVariation In Mean Heart Dose By Treatment Plan Optimization During Radiotherapy For Left Sided Breast Cancer
International Journal of Scientific and Research Publications, Volume 6, Issue 6, June 2016 18 Variation In Mean Heart Dose By Treatment Plan Optimization During Radiotherapy For Left Sided Breast Cancer
More informationRadiotherapy for patients with unresected locally advanced breast cancer
Original Article Radiotherapy for patients with unresected locally advanced breast cancer Caitlin Yee, Yasir Alayed, Leah Drost, Irene Karam, Danny Vesprini, Claire McCann, Hany Soliman, Liying Zhang,
More informationThe sequencing of chemotherapy and radiotherapy in breast cancer patients after mastectomy
Tumori, 96: 28-33, 2010 The sequencing of chemotherapy and radiotherapy in breast cancer patients after mastectomy Hak Jae Kim 1, Jae-Sung Kim 1, Eui Kyu Chie 1, Dong-young Noh 2, Yung-jue Bang 3, Sung
More informationThe New England Journal of Medicine RECURRENCE RATES AFTER TREATMENT OF BREAST CANCER WITH STANDARD RADIOTHERAPY WITH OR WITHOUT ADDITIONAL RADIATION
RECURRENCE RATES AFTER TREATMENT OF BREAST CANCER WITH STANDARD RADIOTHERAPY WITH OR WITHOUT ADDITIONAL RADIATION HARRY BARTELINK, M.D., PH.D., JEAN-CLAUDE HORIOT, M.D., PH.D., PHILIP POORTMANS, M.D.,
More informationPost-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)
Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Conclusions When considering PMRT, use both
More informationBreast cancer: Clinical evidence. of new treatments. Aero academy Conference Innovation and Safety. Patients Come First
Breast cancer: Clinical evidence of new treatments Aero academy Conference Innovation and Safety Patients Come First January 26 & 27, 2018 Lisbon, Portugal Disclosure & Disclaimer An honorarium is provided
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More information